NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.

How would you treat a 30-year-old woman with systemic lupus erythematous (SLE) and lupus nephritis (LN) class 3 with new ...

When added to standard care, more lupus nephritis patients achieved complete remissions with obinutuzumab (Gazyva) than with placebo. Treatment was added to mycophenolate mofetil and glucocorticoids.

Please provide your email address to receive an email when new articles are posted on . At 76 weeks, complete renal response rates were 46.4% with obinutuzumab and 33.1% with placebo. Serious adverse ...

– FDA approval based on superiority of Gazyva over standard therapy alone, as shown in Phase II NOBILITY and Phase III REGENCY data – – Gazyva is the only anti-CD20 monoclonal antibody to demonstrate ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. ACR ...

– Gazyva is the only anti-CD20 monoclonal antibody in a randomized Phase III study to demonstrate a complete renal response benefit – – The filing application is based on data from the Phase III ...

– Nearly half of patients on Gazyva plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvement, compared to standard ...

The total lupus nephritis market size is anticipated to experience growth during the forecast period due to the rising prevalence of lupus nephritis, increasing awareness and adoption of approved ...